利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2698 条记录 (耗时 0.032 秒)

    Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators
    1.
    发明授权
    Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators 有权

    公开(公告)号：US12102642B2

    公开(公告)日：2024-10-01

    申请号：US17983971

    申请日：2022-11-09

    申请人： Corcept Therapeutics Incorporated

    发明人： Andreas G. Moraitis

    IPC分类号： A61K31/567 ,  A61P7/04 ,  G01N33/74

    CPC分类号： A61K31/567 ,  A61P7/04 ,  G01N33/743

    摘要： Novel methods for preventing, reducing the risk of development of, and for treating hypercoagulopathy in Cushing's syndrome patients with elevated risk of developing hypercoagulopathy are disclosed. The methods are further useful to prevent, to reduce the risk of developing, and to treat deep vein thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE); and to treat inflammatory states.
    The methods include: administering heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (HKGRM) to a Cushing's syndrome patient at risk of developing hypercoagulopathy, thereby treating hypercoagulopathy. Methods of preventing, reducing risk of developing, and of treating DVT, PR, or VTE in a Cushing's syndrome patient comprise administering a HKGRM to the patient. Methods of unmasking and subsequently reducing an inflammatory state comprise administering an effective amount of a HKGRM to a Cushing's syndrome patient, effective first to increase inflammatory symptoms and then to subsequently decrease said inflammatory symptoms in the patient.

    CONTENT CONVERSION METHOD OF FREE COMPONENTS BY TRANSFORMING ULTRAFILTRATION TO EQUILIBRIUM DIALYSIS
    2.
    发明公开
    CONTENT CONVERSION METHOD OF FREE COMPONENTS BY TRANSFORMING ULTRAFILTRATION TO EQUILIBRIUM DIALYSIS 审中-公开

    公开(公告)号：US20240319211A1

    公开(公告)日：2024-09-26

    申请号：US18576005

    申请日：2023-05-08

    申请人： HEFEI NOVA-MS BIOTECH MEDICAL EQUIPMENT CO., LTD

    发明人： Jun PENG ,  Zhenzuo JIANG

    IPC分类号： G01N33/74 ,  B01D61/14 ,  B01D61/24 ,  G01N33/68

    CPC分类号： G01N33/74 ,  B01D61/145 ,  B01D61/243 ,  G01N33/6848

    摘要： The present invention belongs to the field of free components detection technologies. For sample preparation of free components, although ultrafiltration is efficient and fast, the temperature is not easy to control which result in the measurement results have a large deviation. Conversely, the temperature is easy to control and measurement results are more precise when equilibrium dialysis is used. However, a long time consumed gives rise to equilibrium dialysis cannot meet the requirement for quickly analyzing clinical biological samples. Therefore, this application provides a content conversion method of free components by transforming ultrafiltration to equilibrium dialysis. Free components are separated from samples by ultrafiltration to obtain first concentration. Meanwhile, free components are separated from the samples by equilibrium dialysis to obtain second concentration. A linear equation is established based on the first concentration and the second concentration, which can meet both requirements of high detection accuracy and short time consuming.

    Method for discharging a patient from an intensive care unit
    7.
    发明授权
    Method for discharging a patient from an intensive care unit 有权

    公开(公告)号：US12000845B2

    公开(公告)日：2024-06-04

    申请号：US17710369

    申请日：2022-03-31

    申请人： B.R.A.H.M.S GmbH

    发明人： Aline Pehla ,  Stefan Kirsch ,  Darius Wilson

    IPC分类号： G01N33/74 ,  G01N33/86

    CPC分类号： G01N33/74 ,  G01N33/86 ,  G01N2800/222 ,  G01N2800/50 ,  G01N2800/52

    摘要： The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

    OXYTOCIN PURIFYING METHOD AND MEASURING METHOD AND KIT
    10.
    发明公开
    OXYTOCIN PURIFYING METHOD AND MEASURING METHOD AND KIT 审中-公开

    公开(公告)号：US20240133901A1

    公开(公告)日：2024-04-25

    申请号：US18278756

    申请日：2022-02-24

    申请人： FUJIFILM Wako Pure Chemical Corporation

    发明人： Masaaki KOJIMA ,  Fumie AKUTSU

    IPC分类号： G01N33/74 ,  G01N1/34

    CPC分类号： G01N33/74 ,  G01N1/34 ,  G01N2410/04

    摘要： An object of the present invention is to provide a simple purifying method, measuring method, and kit. The present invention is an oxytocin purifying method including treating a sample with an acid or a salt thereof, and treating the sample treated with the acid or the salt thereof with a hydrophobic carrier, and related to the purifying method, measuring method including the purifying method, and kit, in which the acid or the salt thereof is at least one or more acids or salts thereof selected from the group consisting of hydrochloric acid, acetic acid, sulfuric acid, sodium hydrogensulfate, potassium hydrogensulfate, lithium hydrogensulfate, ammonium sulfate, and a mixture thereof, and the hydrophobic carrier is a hydrophobic carrier having at least one or more functional groups on the surface, selected from the group consisting of an alkyl group having 4 to 6 carbon atoms, an alkylene glycol group, and a phenyl group.